HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

4th Edition of International Conference on Tissue Engineering and Regenerative Medicine

September 19-21 | Rome, Italy

September 19 -21, 2024 | Rome, Italy
TERMC 2021

Fajar Shodiq Permata

Fajar Shodiq Permata, Speaker at Tissue Engineering Conferences
Universitas Brawijaya, Indonesia
Title : Comparative effects of allograft and xenograft blood to induce hemolytic anaemia in mice

Abstract:

Hemolytic anemia (HA) often attacks dogs and is challenging to treat. HA could be an autoimmune disorder. Therefore it needs an animal model of hemolytic anaemia. For making HA condition, mimicry materials such as blood from allograft or xenograft are used to induce autoimmune to against the blood. The purpose of the research was to examine the comparative effects of allograft and xenograft blood to induce HA in mice. The results were considered based on complete blood count (RBC, WBC, Hb, PCV), blood chemistry (TPP, bilirubin, globulin, BUN, and creatinine), blood smear description, CD4+ and CD8+ of the spleen, and liver, spleen, kidney histopathology. There were three groups, namely negative control, allograft blood induction, xenograft blood induction. Allograft blood was obtained from other mice from a different source. Xenograft blood was obtained from cat blood. The blood was injected intraperitoneally (i.p) 0.2 ml 5 times per week until seven weeks. The results showed that both types of blood induced hemolytic anaemia with a different type and impacted liver, spleen and kidney tissue. Xenograft blood group has a higher (p<0.05) WBC, bilirubin, BUN

level, number of CD4+ and CD8+ cells of spleen and lower (p<0.05), albumin and creatinine level than that of allograft blood group than of allograft. Both allograft and xenograft blood induce the tissue destruction of the spleen, liver and kidney. Conclusions of the research were the allograft blood caused fast hemolytic anemia and the xenograft blood induced the delayed hemolytic anaemia.

Biography:

Fajar, DVM, M.Biotech studied Biomedical Engineering from Biotechnology Master Program at Universitas Gadjah Mada, Indonesia and graduated as MBiotech in 2013. He is a veterinarian (DVM) since 2009. His master thesis was about nerve xenograft from sheep using decellularization techniques. He is a lecturer in the Faculty of Veterinary Medicine, Universitas Brawijaya started in 2013. He has an active researcher, and he achieved research grant Medical ministry of Indonesia in 2015, which developed xeno-cardiac tissue engineering. He got as the best presenter in Nichi-in Regenerative Medicine event in Tokyo, Japan, in 2019. He is one of the panelist in SYIS TERMIS AP in 2021. Now he has 16 Scopus articles.

Watsapp